Mazdutide, a once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, demonstrated good safety and clinically meaningful body weight reduction in Chinese adults with overweight and obesity (−11.3% compared with 1% in placebo) [52]. This evidence concerns the gene GCG and obesity disorder.